Csti-500
Prader-Willi Syndrome
ConSynance TherapeuticsPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
14 Active assets in the Prader-Willi Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Genotropin Corporacion Parc Tauli | Phase 4 | BBB |
Oxytocin University Hospital, Toulouse | Phase 2/3 | BBB |
Dccr Soleno Therapeutics, Inc. | Phase 3 | BB |
Omnitrope University Hospital, Toulouse | Phase 4 | BB |
Guanfacine Maimonides Medical Center | Phase 4 | BB |
View all 33 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →